Significance of TRIUMPH-2 and TRIUMPH-3 Phase 3 Trial Success

Eli Lilly (LLY) has announced the successful completion of the Phase 3 clinical trials for retatrutide, a triple-agonist drug candidate for obesity. In the TRIUMPH-2 trial, which involved patients with obesity and type 2 diabetes, an average weight loss of 20.8% was achieved at week 80. Additionally, the TRIUMPH-3 trial, which included patients with severe obesity and cardiovascular disease, demonstrated an average weight loss of 22.6%. This data represents a significant advancement, as it offers a potent treatment option for high-risk obese patients with comorbidities.

Strong Weight Loss Potential of the 'Triple-G' Mechanism

Retatrutide features a unique 'Triple-G' mechanism, simultaneously activating GLP-1, GIP, and glucagon receptors. This mechanism stimulates a broader range of metabolic pathways compared to existing drugs like Wegovy (semaglutide) from Novo Nordisk (NVO) and Zepbound (tirzepatide) from Lilly. Notably, by promoting glucagon receptors, which increase energy expenditure, the previous TRIUMPH-1 trial achieved an average weight loss of 30%. This suggests that retatrutide could overcome the limitations of existing treatments and offer efficacy comparable to metabolic surgery.

Delayed Approval Application Reflects Manufacturing Considerations

Lilly plans to submit its New Drug Application (NDA) to the FDA in Q1 2027, a delay from the initially planned late 2026. This is not due to efficacy concerns but rather a strategic decision to ensure that the manufacturing and quality control data meet FDA regulatory standards. Given the ongoing shortage of obesity treatments, establishing a robust global supply chain is crucial for the drug's commercial success. The market is responding positively to this approach, prioritizing the long-term availability of the drug over a short-term delay.

Cardiovascular Safety (MACE) and Adverse Event Trends

Throughout the trials, cardiovascular safety indicators were closely monitored in addition to gastrointestinal side effects such as vomiting and diarrhea. In the TRIUMPH-3 trial, the number of major adverse cardiovascular events (MACE-3) was slightly higher in the treatment group (27 events) compared to the placebo group (23 events), raising some concerns. However, the extended evaluation indicator, MACE-5, which includes heart failure and death, showed a trend towards better outcomes in the treatment group. Further investigation into the long-term cardiovascular benefits will be essential for expanding the drug's indications and ensuring its commercial success.

Fierce Competition for Market Leadership in the Global Obesity Market

According to Goldman Sachs, the global obesity treatment market is projected to grow to $114 billion by 2030. Lilly aims to solidify its market dominance with retatrutide, in addition to its existing oral obesity drug, Foundayo (orforglipron). Novo Nordisk is responding with the development of CagriSema, and other players, such as Pfizer (PFE), are also entering the market. Lilly plans to diversify its portfolio with injectables, oral medications, and multi-agonist drugs to maintain its leading position in the obesity treatment market.